back to webinars

Disrupting Drug Development With Digital Biomarkers And The Power Of Precision Health


19 September 2018

time & location

11:00AM, Virtual


Kevin Hrusovsky
President, Chairman and CEO Quanterix Corp; Founder, Powering Precision Health

Dr. Henrik Zetterberg
Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg

Dr. Andrew Nixon, PhD
Associate Professor in Medicine, Member of the Duke Cancer Institute

Watch Now

The webinar, Disrupting Drug Development with Digital Biomarkers and the Power of Precision Health,  provides insights on how Quanterix technology is enabling advances in drug development that have the potential to disrupt drug development processes through the use of ultra sensitive digital biomarkers obtained through minimally invasive sampling techniques. The webinar explores actual use cases across several different disease categories where Quanterix’ digital biomarkers are being used to increase drug safety and efficacy. Hrusovsky, who is also Founder of the Powering Precision Health summit, also solicits perspectives from two leading digital biomarker researchers in the fields of Neurology and Oncology on their latest advances in developing next generation biomarkers on disease progression and minimally invasive early disease detection.

“Ultra sensitive digital biomarkers are catalyzing the potential for diseases to be detected less invasively and earlier in the disease cascade when theoretically the disease is more treatable,” said Hrusovsky. When deployed in drug development, digital biomarkers have the potential to complement traditional clinical endpoints, providing researchers with enhanced mechanistic understanding and measurement of a drug’s efficacy and toxicity at an individual patient level.  These advances in digital biomarker measurement offer the potential for ushering in new treatment options and improving human health.”

Hrusovsky is joined by world-renowned researchers who share how they have deployed biomarker technology in the areas of neurology and oncology research, including:

  • Dr. Henrik Zetterberg, Professor of Neurochemistry and Head of the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy at the University of Gothenburg
  • Dr. Andrew Nixon, Associate Professor in Medicine, Member of the Duke Cancer Institute  

Designed for a wide range of stakeholders in healthcare, the webinar provides a vision for the potential of digital biomarkers and Quanterix technologies to improve drug development processes.